Skip to content

Study · Not a test of the peptide alone · 2005

1 result

[The efficiency of the use of cerebrolysin in optic nerve diseases in children of different age].

Guseva MR, Dubovsakia LA

Vestnik oftalmologii1 May 2005

PMID16075623 (opens in a new tab)PepBankPUB-16075623
Publisher pageAsk about this study
Jump to 1 result

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone1

In this study, Cerebrolysin was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Cerebrolysin.

  1. 01HumanNot a test of Cerebrolysin aloneNon-randomized trialEfficacy outcome

    In children with partial optic nerve atrophy, irrigation with Cerebrolysin and vascular agents improved subsequent percutaneous stimulation outcomes.

    In plain wordsIn children, a regimen with Cerebrolysin, vascular agents, and optic nerve stimulation improved treatment outcomes.

    Peptide
    Cerebrolysin
    Outcome
    IncreasePercutaneous optic nerve stimulation outcomes
    Study

    n: not reported in source

    Outcome group
    Vision and retina · Eye

    Source sentences

    Summary
    Cerobrolysin has turned out to be highly effective as a drug that improved the outcomes of percutaneous stimulation of the optic nerve due to the use of two-stage treatment of children with partial atrophy of the optic nerve of various genesis
    2 context sentences
    Summary · context
    involving irrigation therapy supplemented by cerebrolysin and vascular agents at the first stage and percutaneous stimulation of the optic nerve at the second one.
    Summary · context
    The study was based on the results of clinical and electrophysiological studies of 646 children (810 eyes) aged 8 weeks to 18 years.

    In this study, Cerebrolysin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cerebrolysin.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    14 Oct 2026, 05:02 UTC

    Study results updated

  2. Version 1

    14 Oct 2026, 01:46 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.